Skip to content
RaiseKit
VCsFundsInvestmentsStart freePricing
RaiseKit

The most comprehensive database of web3 VCs. Built and maintained by AI agents.

Directory

  • VCs
  • Funds
  • Investments
  • Writing
  • Funding
  • Sectors
  • Geography

Resources

  • RSS Feed
  • Changelog
  • Search
  • Compare VCs
  • Reports
  • Activity
  • Deploying

Subscribe

Weekly digest of VC insights and funding rounds.

Subscribe to digest →

© 2026 RaiseKit. Data updated nightly by AI agents.

PrivacyTermsSupportDelete accountRSS
  1. Sectors
  2. /Healthtech

Healthtech

100 VCs and 27 funds investing in Healthtech

VCs investing in Healthtech

Elicia McDonald

CEO & Partner

89%

AirTree Ventures (Web3)

Check: Neither Airtree nor Elicia publishes her personal check range or decision authority. Airtree describes itself as seed-first and able to support companies through their journey; a historic Fund III article mentioned a $200k seed entry point, but that is firm- and vintage-specific rather than a current personal range.

Elicia backs highly ambitious, resilient founders from Australia and New Zealand, often beginning at pre-seed or seed and supporting them across later rounds. Her disclosed portfolio spans AI-enabled enterprise software, workforce intelligence, healthcare, agricultural and climate technology, and B2B SaaS. Her writing emphasizes technology's capacity for positive impact, founder ambition, durable relationships, product love, domain depth, and accepting concentrated venture risk in pursuit of outlier outcomes.

Pre-SeedSeedSeries A

Aristos Doxiadis

Partner Emeritus

85%

Big Pi Ventures

Check: No current personal check range: Aristos is Partner Emeritus and an official 2025 biography says he is not involved with Big Pi's later funds. Big Pi's current platform range is €0.5M–€30M across funds, but should not be attributed to him.

Aristos' historical investment lens combines strong technology, team, and market position with realistic commercialization targets. He favors research-based ventures that can bridge academia and industry, secure early adopters beyond a small home market, and use seed or Series A capital to build enough traction for international follow-on funding. His long private-equity career also brings attention to governance, business fundamentals, and social or economic impact.

SeedSeries AEarly Stage

Nick Kalliagkopoulos

Partner

83%

Big Pi Ventures

Check: Firm-wide: Big Pi publishes €0.5M–€30M equity tickets across early-stage and growth funds; its dedicated Growth I strategy leads €7M–€20M+ investments. The site does not publish Nick's personal range, so stage and fund fit must be confirmed per opportunity.

Nick sees biology and robotics as major technology waves and looks for companies using high-quality real-world data, deep technical capability, and customer evidence to automate tasks previously considered impossible. More broadly, he believes Greece's overlooked engineering and biology talent plus its diaspora can support global companies—provided founders internationalize early, raise their ambition, and pair innovation with business development and scalable operations.

SeedSeries ASeries B

Zosia van Eesteren

Senior Associate Therapeutics - Venture&Growth

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Zosia van Eesteren invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Wim Schimmel

Operational Partner

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Wim Schimmel is listed in a Operational Partner capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Wessel van 't Klooster

Analyst - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Wessel van 't Klooster invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Varsha Ram Balapa

Climate Specialist - Support office

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Varsha Ram Balapa is listed in a Climate Specialist - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Tristan Maguet

Senior Associate Therapeutics - Venture&Growth

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Tristan Maguet invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Tom Klein Robbenhaar

General Partner - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Tom Klein Robbenhaar invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Susana Amorim

Investment Director - Venture&Growth

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Susana Amorim invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Stephanie Mooij

Head of Responsible Investment - Support office

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Stephanie Mooij is listed in a Head of Responsible Investment - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Stephan Wachtveitl

Investment Manager - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Stephan Wachtveitl invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Stefan Luzi

Partner Therapeutics - Venture&Growth

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Stefan Luzi invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Stacey Vrijhof

Management Assistant - Support office

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Stacey Vrijhof is listed in a Management Assistant - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Sonia Hallen

Investment Manager Therapeutics - Venture&Growth

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Sonia Hallen invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Silke Kranz

Investment Manager - Climate Solutions

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Silke Kranz invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Senay Sarsik

Office Manager Frankfurt - Support office

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Senay Sarsik is listed in a Office Manager Frankfurt - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Romy Wiering

Management Assistant - Support office

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Romy Wiering is listed in a Management Assistant - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Robert Stein

General Partner - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Robert Stein invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Rik Maerten

Junior Fund Controller - Support office

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Rik Maerten is listed in a Junior Fund Controller - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Redmar Koene

Investment Director - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Redmar Koene invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Raphael Arndt

Associate - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Raphael Arndt invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Rafael Natanek

General Partner - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Rafael Natanek invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Pommeline Korstanje

Associate Public Investments - Venture&Growth

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Pommeline Korstanje invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Pieter van der Meer

Managing Partner

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Pieter van der Meer invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Pheline Mulitze

Analyst - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Pheline Mulitze invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Paulien Schippers

Finance Manager - Support office

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Paulien Schippers is listed in a Finance Manager - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Oksana van Vliet

Legal & AML/KYC counsel - Support office

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Oksana van Vliet is listed in a Legal & AML/KYC counsel - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Nellie Johnson

Executive Assistant - Support office

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Nellie Johnson is listed in a Executive Assistant - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Michel Verhoog

General Partner Climate Solutions

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Michel Verhoog invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Max Steeman

Associate - Climate Solutions

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Max Steeman invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Martin von Berg

Investment Director - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Martin von Berg invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Marloes Herbrink

Finance Assistant - Support office

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Marloes Herbrink is listed in a Finance Assistant - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Marion Pouillard

Senior Associate Therapeutics - Venture&Growth

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Marion Pouillard invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Luna van den Brink

Management Assistant - Support office

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Luna van den Brink is listed in a Management Assistant - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Ludo Suykerbuyk

General Counsel & Compliance Officer - Support office

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Ludo Suykerbuyk is listed in a General Counsel & Compliance Officer - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Lara Hilgert

Senior Associate - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Lara Hilgert invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Katharina Mono

ESG & Impact Analyst - Support office

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Katharina Mono is listed in a ESG & Impact Analyst - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Kate Ebbenhorst

Management Assistant - Support office

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Kate Ebbenhorst is listed in a Management Assistant - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Kasia Lorek

Investment Manager - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Kasia Lorek invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Karthik Bolisetty

Investment Manager Healthtech - Venture&Growth

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Karthik Bolisetty invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Josephine Bogaerts

Investment Manager - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Josephine Bogaerts invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Joep Muijrers

General Partner Public Investments - Venture&Growth

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Joep Muijrers invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Joep Heldens

Investment Manager - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Joep Heldens invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Jelte Goettsch

Senior Associate - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Jelte Goettsch invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Jasper van Gorp

Managing Partner - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Jasper van Gorp invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Janke Dittmer

General Partner Healthtech - Venture&Growth

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Janke Dittmer invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Jan Willem Bakker

Head of Investor Relations / Partner - Support office

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Jan Willem Bakker is listed in a Head of Investor Relations / Partner - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Iskander Shadid

Junior Associate Therapeutics - Venture&Growth

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Iskander Shadid invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Hugo de Bruin

General Partner - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Hugo de Bruin invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Henry Zubaida

Investment Director Healthtech - Venture&Growth

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Henry Zubaida invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Hein Ploegmakers

General Partner Climate Solutions

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Hein Ploegmakers invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Giel Modderman

Associate - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Giel Modderman invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Geoff Pardo

General Partner Healthtech - Venture&Growth

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Geoff Pardo invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Edwin de Graaf

Managing Partner

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Edwin de Graaf invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Edward Hanlon

Investment Director - Venture&Growth

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Edward Hanlon invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Dirkjan Beugelsdijk

CFO - Support office

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Dirkjan Beugelsdijk is listed in a CFO - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Christiaan Sap

Operational Partner

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Christiaan Sap is listed in a Operational Partner capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Chris Allen

Senior Associate HealthTech - Venture&Growth

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Chris Allen invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Camille Sinkora

Analyst - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Camille Sinkora invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Boyd Rutten

Partner - Private Equity

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Boyd Rutten invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Besmire Ahmati

Senior Associate Investor Relations & Fundraising - Support office

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Besmire Ahmati is listed in a Senior Associate Investor Relations & Fundraising - Support office capacity at Gilde Healthcare. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowthPrivate Equity

Arthur Franken

General Partner Healthtech/Therapeutics - Venture&Growth

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Arthur Franken invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Ariane de Marcillac

Associate HealthTech - Venture&Growth

80%

Gilde Healthcare

Check: Gilde Healthcare does not publish one standard check-size range across its strategies on the official site.

Ariane de Marcillac invests or supports investments through Gilde Healthcare's published strategy: Invest through specialist strategies in healthcare technology, therapeutics, care providers and climate solutions that improve health outcomes.

Early StageGrowthPrivate Equity

Philippe Carle

Godfather

80%

OneRagtime

Check: €0.8M-€3M initial investments, as published by OneRagtime.

Philippe Carle is listed in a Godfather capacity at OneRagtime. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

SeedSeries A

Philippe Bourguignon

Godfather

80%

OneRagtime

Check: €0.8M-€3M initial investments, as published by OneRagtime.

Philippe Bourguignon is listed in a Godfather capacity at OneRagtime. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

SeedSeries A

Patrick Sayer

Godfather

80%

OneRagtime

Check: €0.8M-€3M initial investments, as published by OneRagtime.

Patrick Sayer is listed in a Godfather capacity at OneRagtime. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

SeedSeries A

Virginie Morgon

Godmother

80%

OneRagtime

Check: €0.8M-€3M initial investments, as published by OneRagtime.

Virginie Morgon is listed in a Godmother capacity at OneRagtime. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

SeedSeries A

Jean-Marie Messier

Co-founder

80%

OneRagtime

Check: €0.8M-€3M initial investments, as published by OneRagtime.

Jean-Marie Messier is listed in a Co-founder capacity at OneRagtime. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

SeedSeries A

Fortune Max

Senior Full Stack Developer

80%

OneRagtime

Check: €0.8M-€3M initial investments, as published by OneRagtime.

Fortune Max is listed in a Senior Full Stack Developer capacity at OneRagtime. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

SeedSeries A

Emma Veron-Durand

Legal Counsel

80%

OneRagtime

Check: €0.8M-€3M initial investments, as published by OneRagtime.

Emma Veron-Durand is listed in a Legal Counsel capacity at OneRagtime. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

SeedSeries A

Theo Govaers

Investor Relations

80%

OneRagtime

Check: €0.8M-€3M initial investments, as published by OneRagtime.

Theo Govaers is listed in a Investor Relations capacity at OneRagtime. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

SeedSeries A

Louis Pradere

Investor Relations

80%

OneRagtime

Check: €0.8M-€3M initial investments, as published by OneRagtime.

Louis Pradere is listed in a Investor Relations capacity at OneRagtime. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

SeedSeries A

Myriam Bensiali

Finance & Office Manager

80%

OneRagtime

Check: €0.8M-€3M initial investments, as published by OneRagtime.

Myriam Bensiali is listed in a Finance & Office Manager capacity at OneRagtime. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

SeedSeries A

Justine Roux

CFO

80%

OneRagtime

Check: €0.8M-€3M initial investments, as published by OneRagtime.

Justine Roux is listed in a CFO capacity at OneRagtime. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

SeedSeries A

Stéphanie Hospital

Founder & CEO

80%

OneRagtime

Check: €0.8M-€3M initial investments, as published by OneRagtime.

Stéphanie Hospital is listed in a Founder & CEO capacity at OneRagtime. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

SeedSeries A

Samuel Lenoble

Chief Financial Officer

80%

Kerala Ventures

Check: Kerala Ventures does not publish a standard current check-size range on its official site.

Samuel Lenoble is listed in a Chief Financial Officer capacity at Kerala Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Pre-SeedSeed

Olivier Occelli

Cofounder

80%

Kerala Ventures

Check: Kerala Ventures does not publish a standard current check-size range on its official site.

Olivier Occelli is listed in a Cofounder capacity at Kerala Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Pre-SeedSeed

Iness El Haid

VC Investor

80%

OneRagtime

Check: €0.8M-€3M initial investments, as published by OneRagtime.

Iness El Haid invests or supports investments through OneRagtime's published strategy: Back European seed and Series A technology companies across AI consumer, deep tech and technology serving education, climate and health.

SeedSeries A

Antoine Freysz

CEO & Cofounder

80%

Kerala Ventures

Check: Kerala Ventures does not publish a standard current check-size range on its official site.

Antoine Freysz is listed in a CEO & Cofounder capacity at Kerala Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Pre-SeedSeed

Nina Rijnders

Investor Relations

80%

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Nina Rijnders is listed in a Investor Relations capacity at NLC Health Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Pre-SeedSeedVenture Building

Pieter Wijffels

Venture Partner, New Markets

80%

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Pieter Wijffels invests or supports investments through NLC Health Ventures's published strategy: Find, build and scale health innovations from universities, hospitals and corporates, investing alongside founders and external investors.

Pre-SeedSeedVenture Building

Niels van Kasteel

Corporate Account Manager

80%

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Niels van Kasteel is listed in a Corporate Account Manager capacity at NLC Health Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Pre-SeedSeedVenture Building

Kathrin Ballesteros, PhD

Venture Partner, Therapeutics

80%

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Kathrin Ballesteros, PhD invests or supports investments through NLC Health Ventures's published strategy: Find, build and scale health innovations from universities, hospitals and corporates, investing alongside founders and external investors.

Pre-SeedSeedVenture Building

Lydia Kalafateli, PhD

Venture Development Manager

80%

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Lydia Kalafateli, PhD is listed in a Venture Development Manager capacity at NLC Health Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Pre-SeedSeedVenture Building

Henk Westendorp

Venture Partner, Cardiovascular & IGT

80%

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Henk Westendorp invests or supports investments through NLC Health Ventures's published strategy: Find, build and scale health innovations from universities, hospitals and corporates, investing alongside founders and external investors.

Pre-SeedSeedVenture Building

Gina Melchner

Venture Partner, Lead General Healthtech

80%

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Gina Melchner invests or supports investments through NLC Health Ventures's published strategy: Find, build and scale health innovations from universities, hospitals and corporates, investing alongside founders and external investors.

Pre-SeedSeedVenture Building

Taco van der Feltz, MD

Venture Partner

80%

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Taco van der Feltz, MD invests or supports investments through NLC Health Ventures's published strategy: Find, build and scale health innovations from universities, hospitals and corporates, investing alongside founders and external investors.

Pre-SeedSeedVenture Building

Annabel van der Horst

Venture Developer

80%

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Annabel van der Horst is listed in a Venture Developer capacity at NLC Health Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Pre-SeedSeedVenture Building

Ellis Aune

Venture Development Manager

80%

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Ellis Aune is listed in a Venture Development Manager capacity at NLC Health Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Pre-SeedSeedVenture Building

Annameta Gericke

Venture Developer

80%

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Annameta Gericke is listed in a Venture Developer capacity at NLC Health Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Pre-SeedSeedVenture Building

Marta Scali, PhD

Sr. Venture Development Associate

80%

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Marta Scali, PhD is listed in a Sr. Venture Development Associate capacity at NLC Health Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Pre-SeedSeedVenture Building

Gabor Heltovics

Advisor

80%

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Gabor Heltovics is listed in a Advisor capacity at NLC Health Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Pre-SeedSeedVenture Building

Ljudmila Katchan, PhD

Entrepreneur in Residence

80%

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Ljudmila Katchan, PhD is listed in a Entrepreneur in Residence capacity at NLC Health Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Pre-SeedSeedVenture Building

Rita Mendes, PhD

Venture Developer Manager

80%

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Rita Mendes, PhD is listed in a Venture Developer Manager capacity at NLC Health Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Pre-SeedSeedVenture Building

Lars Olthof

Head of Venture Finance, Venture Investment Director

80%

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Lars Olthof is listed in a Head of Venture Finance, Venture Investment Director capacity at NLC Health Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Pre-SeedSeedVenture Building

Jaap Haemers

Investment Manager

80%

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Jaap Haemers invests or supports investments through NLC Health Ventures's published strategy: Find, build and scale health innovations from universities, hospitals and corporates, investing alongside founders and external investors.

Pre-SeedSeedVenture Building

Kevin Ranner

Investment Associate

80%

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Kevin Ranner invests or supports investments through NLC Health Ventures's published strategy: Find, build and scale health innovations from universities, hospitals and corporates, investing alongside founders and external investors.

Pre-SeedSeedVenture Building

Margarida Lopes

Investment Associate

80%

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Margarida Lopes invests or supports investments through NLC Health Ventures's published strategy: Find, build and scale health innovations from universities, hospitals and corporates, investing alongside founders and external investors.

Pre-SeedSeedVenture Building

Ankita Das

Sr. Venture Development Associate

80%

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Ankita Das is listed in a Sr. Venture Development Associate capacity at NLC Health Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Pre-SeedSeedVenture Building

Funds focused on Healthtech

Gilde Healthcare

Utrecht, Netherlands

61 people0 investments

NLC Health Ventures

Amsterdam, Netherlands

37 people0 investments

PurposeTech

Prague, Czechia

26 people0 investments

DeepTech & Climate Fonds

Berlin, Bonn and Munich, Germany

22 people0 investments

LUMO Labs

Eindhoven, Netherlands

21 people0 investments

Capricorn Partners

Leuven, Belgium

20 people0 investments

Integra Partners

Singapore

19 people0 investments

OneRagtime

Paris, France

15 people0 investments

Tilia Impact Ventures

Prague, Czechia

15 people0 investments

Sawari Ventures

Giza, Egypt

13 people0 investments

Sure Valley Ventures

United Kingdom and Ireland

13 people0 investments

node.vc

Stockholm, Sweden

12 people0 investments

Act Venture Capital

Dublin, Ireland

10 people0 investments

Impact X Capital

London, United Kingdom

10 people0 investments

Expon Capital

Luxembourg

8 people0 investments

i&i Bio

Prague, Czechia

8 people0 investments

Alliance VC

Oslo, Norway

8 people0 investments

A-typical Ventures

Doha, Qatar

6 people0 investments

Unconventional Ventures

Copenhagen, Denmark

6 people0 investments

TA Ventures

Global team across North America, Europe, Southeast Asia and MENA

4 people0 investments

Bread & Butter Ventures

Minneapolis, Minnesota

4 people0 investments

Kerala Ventures

Paris, France

3 people0 investments

Fund F

Vienna, Austria

2 people0 investments

INITIATE Ventures

United States

2 people0 investments

Array Ventures

San Francisco, California

2 people0 investments

Auxxo

Berlin, Germany

2 people0 investments

Cake Ventures

San Francisco, California

1 people0 investments